TG Therapeutics Inc. buy stratec
Start price
08.01.18
/
50%
€7.92
Target price
25.09.18
€21.65
Performance (%)
-24.79%
End price
25.09.18
€5.95
Summary
This prediction ended on 25.09.18 with a price of €5.95. The prediction for TG Therapeutics Inc. disappointed with a performance of -24.79%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| TG Therapeutics Inc. | 3.483% | 3.483% | 86.117% | -1.960% |
| iShares Core DAX® | 2.687% | -4.620% | 11.789% | 9.959% |
| iShares Nasdaq 100 | 5.569% | -7.315% | 24.297% | 36.179% |
| iShares Nikkei 225® | 3.756% | -7.813% | 10.017% | 3.466% |
| iShares S&P 500 | 3.959% | -3.697% | 21.637% | 35.681% |
Comments by stratec for this prediction
In the thread TG Therapeutics Inc. diskutieren
stratec stimmt der Buy-Einschätzung von melinda zu
Wainwright's analyst had this to say about the announced deal:
TG Announces Global License Agreement With Jiangsu Hengrui Medicine for Development of NovelBTK Inhibitors TG licenses novel BTK inhibitors that demonstrate superior selectivity to BTK in comparison to ibrutinib in the preclinical setting. On the morning of January 8, TG Therapeutics announced that it has entered into an exclusive global license agreement with Jiangsu Hengrui Medicine, pursuant to which TG will obtain worldwide rights, excluding Asia but including Japan, for the development of Hengrui's BTK inhibitor program. The program includes TG-1701 and TG-1702, both of which are orally-available, covalently-bound BTK inhibitors.
(Vom Mitglied beendet)